IL267195B2 - Use of carbamate compounds for prevention, alleviation or treatment of bipolar disorder - Google Patents

Use of carbamate compounds for prevention, alleviation or treatment of bipolar disorder

Info

Publication number
IL267195B2
IL267195B2 IL267195A IL26719519A IL267195B2 IL 267195 B2 IL267195 B2 IL 267195B2 IL 267195 A IL267195 A IL 267195A IL 26719519 A IL26719519 A IL 26719519A IL 267195 B2 IL267195 B2 IL 267195B2
Authority
IL
Israel
Prior art keywords
bipolar disorder
formula
mania
bipolar
pharmaceutical composition
Prior art date
Application number
IL267195A
Other languages
English (en)
Hebrew (he)
Other versions
IL267195B1 (en
IL267195A (OSRAM
Original Assignee
Sk Biopharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sk Biopharmaceuticals Co Ltd filed Critical Sk Biopharmaceuticals Co Ltd
Publication of IL267195A publication Critical patent/IL267195A/en
Publication of IL267195B1 publication Critical patent/IL267195B1/en
Publication of IL267195B2 publication Critical patent/IL267195B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL267195A 2016-12-14 2017-12-14 Use of carbamate compounds for prevention, alleviation or treatment of bipolar disorder IL267195B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20160170224 2016-12-14
PCT/KR2017/014740 WO2018111008A1 (ko) 2016-12-14 2017-12-14 양극성 장애의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도

Publications (3)

Publication Number Publication Date
IL267195A IL267195A (OSRAM) 2019-07-31
IL267195B1 IL267195B1 (en) 2024-01-01
IL267195B2 true IL267195B2 (en) 2024-05-01

Family

ID=62559442

Family Applications (1)

Application Number Title Priority Date Filing Date
IL267195A IL267195B2 (en) 2016-12-14 2017-12-14 Use of carbamate compounds for prevention, alleviation or treatment of bipolar disorder

Country Status (13)

Country Link
US (1) US11571410B2 (OSRAM)
EP (1) EP3556366B1 (OSRAM)
JP (1) JP7208139B2 (OSRAM)
KR (1) KR102635938B1 (OSRAM)
CN (1) CN110290788A (OSRAM)
AU (1) AU2017374458B2 (OSRAM)
BR (1) BR112019011930A2 (OSRAM)
CL (1) CL2019001618A1 (OSRAM)
IL (1) IL267195B2 (OSRAM)
MX (1) MX2019006940A (OSRAM)
MY (1) MY199104A (OSRAM)
WO (1) WO2018111008A1 (OSRAM)
ZA (1) ZA201903747B (OSRAM)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2978226T3 (es) * 2018-09-21 2024-09-09 Sk Biopharmaceuticals Co Ltd Compuesto de carbamato y uso de la formulación que lo comprende para prevenir, aliviar o tratar el trastorno de estrés agudo o el trastorno de estrés postraumático
CA3113052A1 (en) * 2018-09-21 2020-03-26 Sk Biopharmaceuticals Co., Ltd. Use of carbamate compound for prevention, alleviation, or treatment of status epilepticus
IL293096A (en) * 2019-11-22 2022-07-01 Sk Biopharmaceuticals Co Ltd Oral pharmaceutical composition comprising carbamate compound and preparation method therefor

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006112685A1 (en) * 2005-04-22 2006-10-26 Sk Holdings Co., Ltd. Neurotherapeutic azole compounds
US20120004300A1 (en) * 2010-06-30 2012-01-05 Sk Holdings Co., Ltd. Methods for treating bipolar disorder

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2216305T3 (es) 1997-08-14 2004-10-16 F. Hoffmann-La Roche Ag Vinileteres heterociclicos contra trastornos neurologicos.
CN1251758C (zh) 2000-07-21 2006-04-19 特瓦制药工业有限公司 丙戊酸和2－丙基戊烯酸酰胺的衍生物在制备治疗双极情感障碍症躁狂病药物中的用途
RU2300372C2 (ru) 2001-02-27 2007-06-10 Орто-Макнейл Фармасьютикал, Инк. Карбаматы для применения для предотвращения или лечения биполярного расстройства
JP4276839B2 (ja) 2001-02-27 2009-06-10 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 双極性障害の予防もしくは治療における使用のためのカルバメート化合物
EA200701065A1 (ru) 2004-11-16 2007-12-28 Элан Фарма Интернэшнл Лтд. Инъецируемые составы, содержащие нанодисперсный оланзапин
EP2089011A1 (en) 2006-10-31 2009-08-19 Janssen Pharmaceutica N.V. Treatment of pervasive developmental disorders
US8501436B2 (en) 2009-06-22 2013-08-06 Sk Biopharmaceuticals Co. Ltd. Method for preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester
US8404461B2 (en) 2009-10-15 2013-03-26 SK Biopharmaceutical Co. Ltd. Method for preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester
JP6605020B2 (ja) * 2014-08-15 2019-11-13 ヤンセン ファーマシューティカルズ，インコーポレーテッド Ｎｒ２ｂ受容体阻害剤としてのトリアゾール

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006112685A1 (en) * 2005-04-22 2006-10-26 Sk Holdings Co., Ltd. Neurotherapeutic azole compounds
US20120004300A1 (en) * 2010-06-30 2012-01-05 Sk Holdings Co., Ltd. Methods for treating bipolar disorder

Also Published As

Publication number Publication date
US11571410B2 (en) 2023-02-07
KR20190087572A (ko) 2019-07-24
RU2019121913A3 (OSRAM) 2021-04-21
CN110290788A (zh) 2019-09-27
EP3556366B1 (en) 2025-10-22
IL267195B1 (en) 2024-01-01
US20190314337A1 (en) 2019-10-17
IL267195A (OSRAM) 2019-07-31
CA3046297A1 (en) 2018-06-21
MX2019006940A (es) 2019-09-06
AU2017374458A1 (en) 2019-07-04
AU2017374458B2 (en) 2023-03-02
JP2020502106A (ja) 2020-01-23
EP3556366A4 (en) 2020-06-17
ZA201903747B (en) 2021-01-27
RU2019121913A (ru) 2021-01-15
EP3556366A1 (en) 2019-10-23
CL2019001618A1 (es) 2019-08-23
WO2018111008A1 (ko) 2018-06-21
JP7208139B2 (ja) 2023-01-18
MY199104A (en) 2023-10-13
KR102635938B1 (ko) 2024-02-13
BR112019011930A2 (pt) 2019-10-29

Similar Documents

Publication Publication Date Title
JP7071287B2 (ja) 繊維筋痛又は繊維筋痛の関連する機能的症候群を予防又は治療するためのカルバメート化合物の使用
AU2017374458B2 (en) Use of carbamate compounds for prevention, alleviation or treatment of bipolar disorder
KR102421006B1 (ko) 두통의 예방학적 치료를 위한 카바메이트 화합물의 용도
US20200223838A1 (en) Methods of use of phenoxypropylamine compounds to treat depression
EP3459542B1 (en) Use of carbamate compound for preventing or treating trigeminal neuralgia
IL274431B1 (en) Use of a carbamate compound to reduce or treat developmental disorders including fragile X syndrome, Engelmann syndrome, or Rett syndrome
IL274428B2 (en) Use of a carbamate compound to prevent, relieve or treat a withdrawal seizure or epilepsy presenting with a withdrawal seizure
JP2022503784A (ja) てんかん重積状態の予防、軽減又は治療のためのカルバメート化合物の使用
EP3854391B1 (en) Carbamate compound and use of formulation comprising same in preventing, alleviating, or treating acute stress disorder or post-traumatic stress disorder
RU2774970C2 (ru) Применение карбаматных соединений для профилактики, облегчения или лечения биполярного расстройства
EP3556363B1 (en) Use of carbamate compound for prevention, alleviation or treatment of pruritus
HK40015213A (en) Use of carbamate compounds for prevention, alleviation or treatment of bipolar disorder
RU2796295C2 (ru) Карбаматное соединение и применение включающей его композиции для профилактики, облегчения или лечения острого стрессового расстройства или посттравматического стрессового расстройства
HK40005640B (en) Use of carbamate compound for preventing or treating fibromyalgia or functional syndrome associated with fibromyalgia
HK40005640A (en) Use of carbamate compound for preventing or treating fibromyalgia or functional syndrome associated with fibromyalgia